Milestone Pharmaceuticals...
(MIST)
undefined
undefined%
At close: undefined
1.78
-0.71%
After-hours Dec 13, 2024, 05:31 PM EST
Company Description
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines.
The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.
It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans.
The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Milestone Pharmaceuticals Inc.
| Country | CA |
| IPO Date | May 9, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 47 |
| CEO | Joseph G. Oliveto M.B.A. |
Contact Details
Address: 1111 Dr. Frederik-Philips Boulevard Montreal, QC CA | |
| Website | https://www.milestonepharma.com |
Stock Details
| Ticker Symbol | MIST |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001408443 |
| CUSIP Number | 59935V107 |
| ISIN Number | CA59935V1076 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joseph G. Oliveto M.B.A. | Chief Executive Officer, President & Director |
| Amit Hasija | Chief Financial Officer & Executive Vice President of Corporate Development |
| Jeffrey Nelson | Chief Operating Officer |
| Anita Holz | Vice President & Head of Medical Affairs |
| Dr. David B. Bharucha FACC, M.D., Ph.D. | Chief Medical Officer |
| Dr. Guy Rousseau | SVice President of Regulatory Affairs and Quality Management |
| Dr. Philip T. Sager FACC, FAHA, FHRS, M.D. | Chief Medical Advisor & Member of the Scientific Advisory Board |
| Dr. Philippe Douville M.B.A., Ph.D. | Founder, Strategic Advisor & Member of Scientific Advisory Board |
| Kim Fox | Vice President of Communications |
| Lorenz Muller | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 12, 2024 | S-3 | Filing |
| Nov 12, 2024 | S-8 | Filing |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Oct 29, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Sep 05, 2024 | 4 | Filing |
| Sep 05, 2024 | 3 | Filing |
| Sep 04, 2024 | 8-K | Current Report |
| Aug 29, 2024 | 4 | Filing |
| Aug 29, 2024 | 4 | Filing |